<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    12728159
   </pmid>
   <datecreated>
    <year>
     2003
    </year>
    <month>
     05
    </month>
    <day>
     02
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2003
    </year>
    <month>
     07
    </month>
    <day>
     07
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0040-6376
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       58
      </volume>
      <issue>
       5
      </issue>
      <pubdate>
       <year>
        2003
       </year>
       <month>
        May
       </month>
      </pubdate>
     </journalissue>
     <title>
      Thorax
     </title>
     <isoabbreviation>
      Thorax
     </isoabbreviation>
    </journal>
    <articletitle>
     Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
    </articletitle>
    <pagination>
     <medlinepgn>
      399-404
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      A study was undertaken to record exacerbations and health resource use in patients with COPD during 6 months of treatment with tiotropium, salmeterol, or matching placebos.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Patients with COPD were enrolled in two 6-month randomised, placebo controlled, double blind, double dummy studies of tiotropium 18 micro g once daily via HandiHaler or salmeterol 50 micro g twice daily via a metered dose inhaler. The two trials were combined for analysis of heath outcomes consisting of exacerbations, health resource use, dyspnoea (assessed by the transitional dyspnoea index, TDI), health related quality of life (assessed by St George's Respiratory Questionnaire, SGRQ), and spirometry.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      1207 patients participated in the study (tiotropium 402, salmeterol 405, placebo 400). Compared with placebo, tiotropium but not salmeterol was associated with a significant delay in the time to onset of the first exacerbation. Fewer COPD exacerbations/patient year occurred in the tiotropium group (1.07) than in the placebo group (1.49, p&lt;0.05); the salmeterol group (1.23 events/year) did not differ from placebo. The tiotropium group had 0.10 hospital admissions per patient year for COPD exacerbations compared with 0.17 for salmeterol and 0.15 for placebo (not statistically different). For all causes (respiratory and non-respiratory) tiotropium, but not salmeterol, was associated with fewer hospital admissions while both groups had fewer days in hospital than the placebo group. The number of days during which patients were unable to perform their usual daily activities was lowest in the tiotropium group (tiotropium 8.3 (0.8), salmeterol 11.1 (0.8), placebo 10.9 (0.8), p&lt;0.05). SGRQ total score improved by 4.2 (0.7), 2.8 (0.7) and 1.5 (0.7) units during the 6 month trial for the tiotropium, salmeterol and placebo groups, respectively (p&lt;0.01 tiotropium v placebo). Compared with placebo, TDI focal score improved in both the tiotropium group (1.1 (0.3) units, p&lt;0.001) and the salmeterol group (0.7 (0.3) units, p&lt;0.05). Evaluation of morning pre-dose FEV(1), peak FEV(1) and mean FEV(1) (0-3 hours) showed that tiotropium was superior to salmeterol while both active drugs were more effective than placebo.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Exacerbations of COPD and health resource usage were positively affected by daily treatment with tiotropium. With the exception of the number of hospital days associated with all causes, salmeterol twice daily resulted in no significant changes compared with placebo. Tiotropium also improved health related quality of life, dyspnoea, and lung function in patients with COPD.
     </abstracttext>
    </abstract>
    <affiliation>
     Facoltà di Medicina e Chirurgia, Università di Genova, Genova, Italy. brusasco@dism.unige.it
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Brusasco
      </lastname>
      <forename>
       V
      </forename>
      <initials>
       V
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Hodder
      </lastname>
      <forename>
       R
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Miravitlles
      </lastname>
      <forename>
       M
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Korducki
      </lastname>
      <forename>
       L
      </forename>
      <initials>
       L
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Towse
      </lastname>
      <forename>
       L
      </forename>
      <initials>
       L
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kesten
      </lastname>
      <forename>
       S
      </forename>
      <initials>
       S
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     England
    </country>
    <medlineta>
     Thorax
    </medlineta>
    <nlmuniqueid>
     0417353
    </nlmuniqueid>
    <issnlinking>
     0040-6376
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Bronchodilator Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Scopolamine Derivatives
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      136310-93-5
     </registrynumber>
     <nameofsubstance>
      tiotropium
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      18559-94-9
     </registrynumber>
     <nameofsubstance>
      Albuterol
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      89365-50-4
     </registrynumber>
     <nameofsubstance>
      salmeterol
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      Life Sci. 1999;64(6-7):457-64
     </refsource>
     <pmid version="1">
      10069510
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Chest. 1999 Mar;115(3):635-41
     </refsource>
     <pmid version="1">
      10084468
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418-22
     </refsource>
     <pmid version="1">
      9603117
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Respir Crit Care Med. 1997 Apr;155(4):1283-9
     </refsource>
     <pmid version="1">
      9105068
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Life Sci. 1995;56(11-12):853-9
     </refsource>
     <pmid version="1">
      10188785
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Chest. 1999 Apr;115(4):957-65
     </refsource>
     <pmid version="1">
      10208192
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Antimicrob Chemother. 1999 Mar;43 Suppl A:107-13
     </refsource>
     <pmid version="1">
      10225580
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Respir Crit Care Med. 1999 Aug;160(2):542-9
     </refsource>
     <pmid version="1">
      10430726
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Thorax. 1999 Nov;54(11):995-1003
     </refsource>
     <pmid version="1">
      10525558
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 2000 May 13;320(7245):1297-303
     </refsource>
     <pmid version="1">
      10807619
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Pharmacoeconomics. 2001;19(3):245-54
     </refsource>
     <pmid version="1">
      11303413
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Respir Crit Care Med. 2001 Apr;163(5):1087-92
     </refsource>
     <pmid version="1">
      11316640
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Eur Respir J. 2002 Feb;19(2):217-24
     </refsource>
     <pmid version="1">
      11866001
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Eur Respir J. 2002 Feb;19(2):209-16
     </refsource>
     <pmid version="1">
      11871363
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am Rev Respir Dis. 1992 Jun;145(6):1321-7
     </refsource>
     <pmid version="1">
      1595997
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Intern Med. 1987 Feb;106(2):196-204
     </refsource>
     <pmid version="1">
      3492164
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Chest. 1984 Jun;85(6):751-8
     </refsource>
     <pmid version="1">
      6723384
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Chest. 1994 Sep;106(3):904-12
     </refsource>
     <pmid version="1">
      8082376
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Chest. 1993 Dec;104(6):1743-7
     </refsource>
     <pmid version="1">
      8252955
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Respir Crit Care Med. 1996 Mar;153(3):967-75
     </refsource>
     <pmid version="1">
      8630581
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Thorax. 2006 Jan;61(1):91
     </refsource>
     <pmid version="1">
      16396956
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      ACP J Club. 2003 Nov-Dec;139(3):64
     </refsource>
     <pmid version="1">
      14594415
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="ErratumIn">
     <refsource>
      Thorax. 2005 Feb;60(2):105
     </refsource>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Inhalation
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Albuterol
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bronchodilator Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dyspnea
     </descriptorname>
     <qualifiername majortopicyn="N">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Forced Expiratory Volume
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hospitalization
     </descriptorname>
     <qualifiername majortopicyn="N">
      statistics &amp; numerical data
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Metered Dose Inhalers
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Pulmonary Disease, Chronic Obstructive
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      physiopathology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Quality of Life
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Scopolamine Derivatives
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Vital Capacity
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC1746668
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2003
     </year>
     <month>
      5
     </month>
     <day>
      3
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2003
     </year>
     <month>
      7
     </month>
     <day>
      8
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2003
     </year>
     <month>
      5
     </month>
     <day>
      3
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     12728159
    </articleid>
    <articleid idtype="pmc">
     PMC1746668
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

